Dashboard
Manage Tickers

MRNA Moderna, Inc.

Nasdaq modernatx.com


$ 27.20 $ -0.98 (-3.48 %)    

Friday, 31-Oct-2025 19:55:14 EDT
CLICK TO SEE RELEVANT LITIGATION UPDATES
Y-mAbs Therapeutics, Inc. | YMAB | Take Action!
QQQ $ 629.16 $ 3.02 (0.48 %)
DIA $ 475.58 $ 0.66 (0.14 %)
SPY $ 681.80 $ 2.23 (0.33 %)
TLT $ 90.21 $ -0.27 (-0.3 %)
GLD $ 368.20 $ -2.01 (-0.54 %)
$ 27.16
$ 27.77
$ 27.12 x 301
$ 27.39 x 500
$ 26.87 - $ 27.87
$ 23.15 - $ 56.70
15,696,522
na
10.57B
$ 1.12
nm
TBD
na
na ($ 0.00)
na
TBD na
How to Read 10-K & 10-Q Reports To View SEC Filing Reports, Please Register or Sign In
# Filing Date Period End Date Type Report Link
1 08-01-2025 06-30-2025 10-Q
2 05-01-2025 03-31-2025 10-Q
3 02-21-2025 12-31-2024 10-K
4 11-07-2024 09-30-2024 10-Q
5 08-01-2024 06-30-2024 10-Q
6 05-02-2024 03-31-2024 10-Q
7 02-23-2024 12-31-2023 10-K
8 11-03-2023 09-30-2023 10-Q
9 08-03-2023 06-30-2023 10-Q
10 05-04-2023 03-31-2023 10-Q
11 02-24-2023 12-31-2022 10-K
12 11-03-2022 09-30-2022 10-Q
13 08-03-2022 06-30-2022 10-Q
14 05-04-2022 03-31-2022 10-Q
15 02-25-2022 12-31-2021 10-K
16 11-04-2021 09-30-2021 10-Q
17 08-05-2021 06-30-2021 10-Q
18 05-06-2021 03-31-2021 10-Q
19 02-26-2021 12-31-2020 10-K
20 10-30-2020 09-30-2020 10-Q
21 08-06-2020 06-30-2020 10-Q
22 05-07-2020 03-31-2020 10-Q
23 02-27-2020 12-31-2019 10-K
24 11-06-2019 09-30-2019 10-Q
25 08-08-2019 06-30-2019 10-Q
26 05-09-2019 03-31-2019 10-Q
27 03-13-2019 12-31-2018 10-K
Guide for Analyst Ratings To View Analyst Ratings, Please Register or Sign In
# Date Analyst Firm Upside/Downside Price Target Change Rating Change Current Rating

News

OPINIONS

moderna-mrna-stock-is-trading-lower-friday-whats-going-on
Moderna (MRNA) Stock Is Trading Lower Frid...
10/31/2025 19:57:43

Moderna shares are trading lower Friday afternoon, giving back a portion of gains seen Thursday.

Core News & Articles
10 Health Care Stocks Whale Activity In To...
10/30/2025 17:35:24

is-moderna-inc-gaining-or-losing-market-support
Is Moderna Inc Gaining or Losing Market Su...
10/30/2025 16:00:50

watching-moderna-shares-spike-higher-traders-circulate-unconfirmed-rumor-company-has-been-in-talks-to-be-acquired-with-at-least-one-large-drugmaker-on-a-deal-of-significant-scope-a-person-familiar-with-the-discussions-told-stat
Watching Moderna; Shares Spike Higher, Tra...
10/30/2025 15:14:37

https://www.statnews.com/2025/10/30/moderna-rise-fall-biotech-analysis-from-pandemic-rise-to-mrna-crash

Core News & Articles
'US Fires Top Health Official Who Opposed ...
10/28/2025 12:50:58

https://www.bloomberg.com/news/articles/2025-10-28/us-fires-top-health-official-who-opposed-widely-used-covid-shots?srnd=homepa...

ubs-maintains-buy-on-moderna-lowers-price-target-to-40
UBS Maintains Buy on Moderna, Lowers Price...
10/23/2025 21:02:15

UBS analyst Eliana Merle maintains Moderna (NASDAQ:MRNA) with a Buy and lowers the price target from $70 to $40.

jp-morgan-maintains-underweight-on-moderna-lowers-price-target-to-25
JP Morgan Maintains Underweight on Moderna...
10/23/2025 16:18:24

JP Morgan analyst Jessica Fye maintains Moderna (NASDAQ:MRNA) with a Underweight and lowers the price target from $26 to $25.

moderna-stops-cmv-program-as-vaccine-falls-short-in-preventing-infection
Moderna Stops CMV Program As Vaccine Falls...
10/23/2025 14:26:15

Moderna ends its CMV vaccine program after a Phase 3 trial failed to meet efficacy goals, but maintains its 2028 breakeven and ...

citigroup-maintains-neutral-on-moderna-lowers-price-target-to-28
Citigroup Maintains Neutral on Moderna, Lo...
10/23/2025 10:59:18

Citigroup analyst Geoff Meacham maintains Moderna (NASDAQ:MRNA) with a Neutral and lowers the price target from $30 to $28.

moderna-reports-that-its-phase-3-trial-for-investigational-cmv-vaccine-mrna-1647-did-not-meet-its-primary-efficacy-endpoint-in-preventing-cmv-infection-among-seronegative-women-aged-1640-the-company-will-discontinue-its-congenital-cmv-clinical-development-program
Moderna Reports That Its Phase 3 Trial For...
10/22/2025 20:13:30

Moderna, Inc. (NASDAQ:MRNA) today announced topline results from a Phase 3 pivotal trial evaluating the efficacy of mRNA-1647, ...

wellgistics-and-datavault-team-up-to-transform-prescription-tracking
Wellgistics And DataVault Team Up To Trans...
10/22/2025 12:30:33

DataVault AI and Wellgistics Health are collaborating to bring blockchain technology to the US prescription drug market.

dow-jumps-more-than-500-points-ahead-of-earnings-investor-fear-eases-greed-index-remains-in-fear-zone
Dow Jumps More Than 500 Points Ahead Of Ea...
10/21/2025 07:54:45

U.S. stocks rise on Monday, with the Dow up 500+ points. Moderna and Cleveland-Cliffs report gains. Most S&P sectors close ...

small-caps-rally-as-credit-fears-ease-gold-rebounds-to-4350-whats-moving-markets-monday
Small Caps Rally As Credit Fears Ease, Gol...
10/20/2025 19:18:58

Wall Street rallied to start the week, with small-cap stocks and regional banks rebounding sharply after last week's credit...

needham-reiterates-hold-on-modernato-hold
Needham Reiterates Hold on Modernato Hold
10/20/2025 10:03:57

Needham analyst Joseph Stringer reiterates Moderna (NASDAQ:MRNA) from Hold to Hold.

stock-market-today-sp-500-nasdaq-dow-jones-futures-rise-micron-bitmine-coinbase-in-focus
Stock Market Today: S&P 500, Nasdaq, Dow J...
10/20/2025 09:15:59

U.S. stock futures rose on Monday following Friday’s advances. Futures of major benchmark indices were higher.

reported-sunday-moderna-showcases-mrna-1010-and-mrna-1018-data-demonstrating-rapid-immune-response-and-no-safety-concerns-across-adult-populations-at-idweek-2025
Reported Sunday, Moderna Showcases mRNA-10...
10/20/2025 07:31:16

hedge-fund-shah-capital-urges-novavax-to-consider-sale-amid-vaccine-rollout-struggles-sees-5-billion-potential
Hedge Fund Shah Capital Urges Novavax To C...
10/14/2025 17:08:17

Shah Capital urges Novavax to consider a sale after poor COVID-19 vaccine rollout, highlighting the potential value of at least...

moderna-reports-promising-response-rates-for-skin-cancer-combo-therapy-in-resistant-patients
Moderna Reports Promising Response Rates F...
10/13/2025 14:52:30

Moderna's Phase 1/2 study shows mRNA-4359 plus pembrolizumab yields 24% response rate and 60% disease control in resistant ...

reported-sunday-moderna-presents-early-phase-12-data-showing-24-response-rate-for-mrna-4359-in-checkpoint-inhibitor-resistant-melanoma
Reported Sunday, Moderna Presents Early Ph...
10/13/2025 06:35:50

mRNA-4359 has advanced into the Phase 2 portion of the ongoing Phase 1/2 trial

4-analysts-assess-moderna-what-you-need-to-know
4 Analysts Assess Moderna: What You Need T...
10/10/2025 21:01:51

CORE & Plaid

CORE & Plaid

CORE Finalist

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION